August 23, 2012 8:08 PM | 1 min read |
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq: MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), announced positive preliminary results of a Phase 1b clinical trial involving multiple administrations of intravenous (IV) MN-221 (bedoradrine) over several days in patients with stable, moderate-to-severe chronic obstructive pulmonary disease (COPD). The majority of the subjects completed the study and there were no clinically significant safety concerns. In addition, preliminary pharmacokinetic and efficacy findings were encouraging. "We are very pleased with the positive safety data and early efficacy findings for MN-221," said Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc. "These results add important value to our ongoing strategic development of our pivotal clinical program for MN-221 and we look forward to discussing this data at our upcoming End-of-Phase 2 meeting with the FDA's respiratory division in late October." A total of 25 subjects were randomized to placebo (5 subjects) or MN-221 (20 subjects) treatment groups; with similar enrollment at each of two clinical research units. The patient group included those who had concomitant illnesses and were using other medications that are
See full press release
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.